New drug cocktail may tame deadly transplant complication
NCT ID NCT05621759
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of three drugs (cyclophosphamide, abatacept, and tacrolimus) given at lower doses to prevent graft-versus-host disease (GVHD) in 27 adults receiving a stem cell transplant from a half-matched donor. GVHD is a serious condition where donor cells attack the patient's body. The goal is to see if this approach reduces GVHD while causing fewer side effects. Participants will be followed for up to two years after transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT VS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test outsmart deadly fungal infections in blood cancer?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a safer dose of an old drug shield vulnerable children from deadly fungal infections?
- Can a lower drug dose make stem cell transplants safer?
- Plant pigment could soothe Radiation's harsh side effect in blood cancer treatment
- New Antibody-Drug conjugate targets Hard-to-Treat cancers